Live Chat ×
Skip to main content

Practical Updates in Lymphoma

Evaluated by: 
David B. Kaminsky, M.D., FIAC, April 11, 2018
Original release date: May 23, 2018
Access to this course expires on:  April 11, 2021, at 11:59 PM Pacific Time
CME 15.5
SAMs 15.25

Course Description
Lymphomas are highly heterogeneous, consisting of numerous clinicopathologic subtypes and variants whose diagnosis and classification require integration of histologic, immunophenotypic, clinical, molecular and genomic parameters. Furthermore, there is rapid evolution of molecular prognostic factors and therapeutic markers that have clinical impact and challenge pathologists. This interactive microscopy course, supplemented by lectures, highlights the practical aspects of important changes impacting the diagnostic approach to indolent and aggressive B cell lymphomas, Hodgkin lymphoma and T cell lymphoma.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:

  • Improve ability to diagnose indolent and aggressive B cell lymphomas, Hodgkin Lymphoma and T cell lymphoma 
  • Refine skills related to the use of immunohistochemical and molecular studies to identify clinically relevant subtypes of indolent and aggressive B cell lymphomas and T cell lymphomas 
  • Enhance ability to distinguish diffuse large B cell lymphomas (DLBCLs) from other aggressive B cell lymphomas 
  • Better distinguish Hodgkin lymphoma from other B or T cell lymphomas 
  • Enhance capability of evaluating lymphomas for clinically relevant targeted therapy  

Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 15.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 15.5 SAM/Part II credit hours.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty and coordinator reported no relevant financial relationships: Megan S. Lim, M.D., Ph.D., Nathanael Bailey, M.D., Kojo S. J. Elanitoba-Johnson, M.D., L. Jeffrey Medeiros, M.D.

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME and SAM credit, all learners must take a content-based exam and achieve a minimum score of 80%. If learners do not achieve a passing score of 80%, they have the option to retake the exam. After you pass the test and complete the evaluation, your certificate of completion will be available to view and print by clicking here.  

Buy the entire Practical Updates in Lymphoma course and get a great discount!
Not A Member? Click Here